Searches for semaglutide weight loss reviews have multiplied since Wegovy’s FDA approval in 2021, and the reviews themselves tell a more nuanced story than either the trial data or the marketing. Real-world patients consistently report the same core narrative: modest early weight loss of 4 to 8 pounds in the first month, meaningful side effects during titration, steady loss through months three to six, and a mix of maintenance success and struggle after month nine. This article combines published trial data with patterns seen across thousands of published patient reviews on forums, healthcare sites, and clinical follow-up studies to give you a grounded picture of what to expect. For a foundational overview, see our wellness guide.
What the Trial Data Says — and What Reviews Add
The pivotal STEP-1 trial showed average weight loss of 14.9 percent over 68 weeks on semaglutide 2.4 mg weekly (Wegovy), versus 2.4 percent on placebo. Those are well-documented numbers. What reviews add is the texture: how patients actually experience the drug week to week, where their expectations break down, and how real-world results differ from tightly controlled trial conditions.
Published reviews and large real-world cohort studies suggest average weight loss in actual practice runs slightly lower than trial outcomes — often 10 to 12 percent rather than 15 percent — largely because patients discontinue treatment at higher rates than in trials, skip doses more often, and sometimes cannot titrate to the target dose due to side effects. For a side-by-side with tirzepatide, see our GLP-1 weight loss guide.
Month One: The Hardest Period
First-month reviews cluster around a common set of experiences. Patients start at 0.25 mg weekly, which is a sub-therapeutic dose used for tolerance induction. Weight loss is typically minimal at this stage (1 to 4 pounds), but appetite reduction is already noticeable by week two for many users. Nausea, often mild, appears in the first three or four days after each dose. Constipation and fatigue are frequently mentioned alongside.
Reviewers who struggle most in month one usually describe combinations of severe nausea, vomiting, diarrhea, or significant fatigue — side effects that cause some patients to discontinue before reaching any meaningful dose. Those who tolerate the first month well generally find side effects easier to manage as titration proceeds.
Months Two Through Six: The Loss Phase
By month three, most reviewers who stay on semaglutide report steady weekly weight loss, reduced hunger, and diminished “food noise.” Average cumulative loss at 12 weeks is 6 to 10 percent of starting body weight for patients who reach the 1.0 mg or 1.7 mg dose. Clothing fit changes become noticeable, energy typically improves, and many reviewers describe the experience as “finally feeling in control of eating.”
Weeks after dose escalations are often marked by renewed nausea or indigestion, then improvement within several days. By month six, most trial-equivalent patients are at the 2.4 mg maintenance dose and have lost 10 to 15 percent of their starting weight. Reviews at this stage tend to be the most positive, with reviewers commenting on improved blood pressure, reduced joint pain, better sleep, and improved energy.
Months Nine and Beyond: Plateaus and Maintenance
Longer-term reviews are where the narrative becomes more varied. Some patients continue losing weight through months 12 to 18, reaching total losses of 18 to 22 percent. Others plateau around month nine at 10 to 13 percent loss and hold steady. A smaller group experiences rebound regain despite continuing therapy, which clinicians attribute to incomplete dose escalation, adherence gaps, or individual biology.
What virtually all long-term reviewers agree on is that stopping semaglutide leads to weight regain. The STEP-4 trial showed patients who switched from semaglutide to placebo regained roughly two-thirds of lost weight within a year, and real-world reviews confirm this pattern consistently. Obesity specialists now treat the drug as long-term therapy rather than a short-term course. See our Wegovy dosing schedule for detailed titration information.
Common Side Effect Themes in Reviews
Reviewers consistently highlight several side effects as the most challenging. Nausea is the most universally mentioned, peaking during the first few days after each dose and after dose escalations. Constipation is the second most-cited complaint, often requiring hydration, fiber, and occasionally a stool softener. Fatigue during the first month is frequent, often resolving after titration.
Less common but significant concerns in real-world reviews include acid reflux, sulfur burps (an unusual gastrointestinal symptom uniquely associated with GLP-1 drugs), hair thinning during rapid weight loss, and facial volume loss sometimes called “Ozempic face.” None of these are formally listed in the drug’s prescribing information beyond the gastrointestinal categories, but they appear consistently enough across reviews to be worth discussing with your prescriber.
What Reviewers Wish They’d Known Earlier
A striking pattern in retrospective reviews is the list of things patients say they wish they had known at the start. Titrate slowly even if you feel fine. Hydrate aggressively from day one. Eat smaller, more frequent meals low in fat. Avoid greasy and fried foods entirely during titration. Start a protein-focused eating pattern immediately to preserve lean mass as weight drops.
Patients also wish they had understood the long-term nature of the drug before starting. Many began assuming they would use semaglutide for six months, lose weight, and stop — only to be surprised by rapid regain and the realization that most obesity specialists view these drugs as long-term therapy. Setting that expectation from the start makes the decision more informed.
Who Reviews Well and Who Doesn’t
Reviews tend to be most positive from patients with higher starting BMIs (35 or greater), patients with obesity-related comorbidities like prediabetes or hypertension, and patients who pair the drug with consistent protein intake and some form of physical activity. Reviews are mixed from patients with lower BMIs who stretched off-label access for modest cosmetic weight loss goals, and reviews are most negative from patients who experienced severe gastrointestinal side effects and discontinued early.
Demographic data from large cohort studies suggest women report slightly better average weight loss than men, and patients with type 2 diabetes lose somewhat less weight on average than patients without diabetes — a finding confirmed across STEP, SUSTAIN, and real-world registries. See also our Wegovy cost guide.
Frequently Asked Questions
How much weight do most people lose on semaglutide?
Real-world average loss is roughly 10 to 12 percent of body weight over 12 to 18 months, slightly below the 15 percent seen in STEP-1 trial conditions. Individual results range from under 5 percent to over 25 percent depending on adherence, dose tolerance, and starting weight.
How fast does semaglutide start working?
Most reviewers notice appetite reduction within the first one to two weeks, measurable weight loss by week three or four, and the most dramatic monthly losses during months two through six as dose escalation proceeds.
What are the most common complaints in semaglutide reviews?
Nausea, constipation, fatigue during the first month, sulfur burps, and the cost of the medication are the most frequently cited challenges. Severe or persistent side effects cause a significant minority of patients to discontinue.
Do most people keep the weight off after stopping?
No. Most reviewers and trial data agree that stopping semaglutide leads to substantial weight regain within 6 to 18 months, often amounting to two-thirds or more of the lost weight returning. Long-term therapy is the norm for patients who want to maintain results.
Is semaglutide worth it based on reviews?
Reviews lean positive from patients who tolerated the drug, reached therapeutic doses, and saw meaningful weight loss and comorbidity improvements. They lean negative from patients who experienced severe side effects, could not afford continued therapy, or had unrealistic expectations of rapid dramatic loss.
The Bottom Line on Semaglutide Reviews
Semaglutide weight loss reviews converge on a consistent picture: meaningful weight loss for most patients who can tolerate titration, significant but usually manageable gastrointestinal side effects, real improvements in weight-related conditions, and weight regain when the drug is stopped. Real-world results run somewhat lower than trial averages but are still substantially better than any prior weight-loss drug class. If you are considering starting, discuss realistic expectations with your prescriber, plan for long-term use, prepare for titration side effects, and focus on dietary and activity habits that will support sustained progress.